372090-70-5

Basic information

• Product Name: 7-benzyl-1,3-dichloro-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile
• Synonyms: 7-benzyl-1,3-dichloro-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile
• CAS NO: 372090-70-5
• Molecular Formula: C16H13Cl2N3
• Molecular Weight: 318.205
• Mol File: 372090-70-5.mol

Chemical Properties

• Melting Point: 220 - 223 °C
• CAS DataBase Reference: 7-benzyl-1,3-dichloro-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 7-benzyl-1,3-dichloro-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile(372090-70-5)
• EPA Substance Registry System: 7-benzyl-1,3-dichloro-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile(372090-70-5)

Safety Data

• Hazardous Substances Data: 372090-70-5(Hazardous Substances Data)

Upstream product

• 1228692-26-9 7-benzyl-1,3-dioxo-1,2,3,4,5,6,7,8-octahydro-[2,7]-naphthyridine-4-carbonitrile 
• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 
• 6938-07-4 N,N-bis(2-ethoxycarbonylethyl)benzylamine 

Downstream Products

• 1228692-32-7 C₂₁H₂₂ClFN₄ 
• 327100-92-5 C₂₂H₂₅ClN₄ 
• 1228692-35-0 C₁₈H₁₉ClN₄ 
• 1228692-36-1 C₁₉H₂₁ClN₄ 
• 1228692-37-2 C₂₂H₁₉ClN₄ 
• 1454657-67-0 7-(3-tert-butoxycarbonyl-phenyl)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carboxylic acid methyl ester 
• 1454657-68-1 3-[5-(methoxycarbonyl)-3,4-dihydro-2,7-naphthyridin-2(1H)-yl]benzoic acid 
• 1454657-24-9 methyl 7-(3-{[(3-isopropylphenyl)amino]carbonyl}phenyl)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carboxylate 
• 1454657-25-0 7-(3-{[(3-isopropylphenyl)amino]carbonyl}phenyl)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carboxylic acid 
• 1454657-26-1 methyl 7-[3-({[3-(trifluoromethyl)phenyl]amino}carbonyl) phenyl]-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carboxylate 
• 1454657-27-2 7-(3-{[(3-isopropylphenyl)amino]carbonyl}phenyl)-N-(3-morpholin-4-ylpropyl)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carboxamide 
• 1454657-28-3 N-(3-hydroxypropyl)-7-(3-{[(3-isopropylphenyl)amino]carbonyl}phenyl)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carboxamide 
• 1454657-29-4 methyl ({[7-(3-{[(3-isopropylphenyl)amino]carbonyl}phenyl)-5,6,7,8-tetrahydro-2,7-naphthyridin-4-yl]carbonyl}amino)acetate 
• 1454657-30-7 7-(3-{[(3-isopropylphenyl)amino]carbonyl}phenyl)-N-(3-pyrrolidin-1-ylpropyl)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carboxamide 

Relevant articles and documents

New heterocyclic systems derived from pyridine: New substrates for the investigation of the azide/tetrazole equilibrium

By exploiting the reactivity of 7-alkyl-3-chloro-4-cyano-1-hydrazino-5,6,7,8-tetrahydro-2,7-naphthyridines 5 some 7-alkyl-1-azido-3-chloro-4-cyano-5,6,7,8-tetrahydro-2,7-naphthyridines 6 were synthesized. Looking at their chemical properties we have ascer

KINASE INHIBITORS

The present invention relates to compounds of formulae I and II wherein the variables are as defined herein. These compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS

The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists

The original structure of a high-throughput screening hit obtained from an external vendor was revised based on multiple NMR studies. The active compound was re-synthesized via a novel route and its structure and biological activity as a BRS-3 agonist were unambiguously confirmed. Multi-gram quantities of the hit were prepared for pharmacokinetic and efficacy studies. The synthetic strategy allowed for the preparation of multiple analogs for SAR exploration.